Wall Street got a jolt on Tuesday as Medline’s private equity backers moved to unload a huge chunk of stock, putting about 75 million Class A shares on the market in a secondary sale that could top $3 billion at current prices. The shares are all coming from existing investors that helped take the Northfield-based medical supplies company private, and not from Medline itself, but the stock still came under pressure once the plan went public.
Who Is Selling And What Is On The Block
According to pr.comtex.com, stockholders affiliated with Blackstone, Carlyle, Hellman & Friedman and a wholly owned subsidiary of the Abu Dhabi Investment Authority "have commenced an underwritten public offering" of 75,000,000 Class A shares. They also intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares.
Medline stressed that it is not selling any shares in this transaction and will not receive any proceeds from the offering. The filing lists Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan as global coordinators for the deal.
Market Reaction And The Valuation Math
The news quickly hit the stock, with shares trading lower in premarket action as Investing.com reported. At prices in the low to mid 40s per share, the roughly 75 million share block comes out to around $3.2 billion, while some outlets have rounded that to about $3.4 billion. The sheer size of the sale and the heavyweight sponsor roster are the key forces driving the market’s reaction.
How This Fits Into Medline’s Wall Street Run
Medline only recently pulled off a blockbuster IPO in December that raised roughly $6.26 billion and delivered a lucrative public debut for its private equity sponsors. A consortium led by Blackstone, Carlyle, and Hellman & Friedman had taken a majority stake in the company in 2021 in a deal valued at about $34 billion. This secondary offering is a predictable follow-up for sponsors looking to lock in liquidity after a strong listing, Reuters noted.
What Comes Next For Medline Investors
The registration statement for the offering still has to become effective before any shares can actually change hands, and the underwriters will have a standard 30-day window to exercise the option for additional shares to cover any overallotments, according to the company filing. Investors will be watching to see whether the sponsors decide to trim more of their holdings after this block and how trading volume responds as the deal moves forward.
For now, Medline says it will not receive any proceeds from the sale and that further specifics will be laid out in the prospectus and related SEC filings tied to the offering, as outlined in the company release.
